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Abstract
Aim—To describe the knowledge and attitudes of clinicians participating in a large 
pharmacogenomics implementation program.
Materials & methods—Semi-structured interviews with 15 physicians and nurse practitioners 
were conducted.
Results—Three categories of themes were identified: preparation and knowledge, 
pharmacogenomics usage in practice, and future management of genomic variants. Providers 
expressed an inability to keep up with the rapid pace of evidence generation and indicated strong 
support for clinical decision support to assist with genotype-tailored therapies. Concerns raised by 
clinicians included effectively communicating results, long-term responsibility for actionable 
results and hand-offs with providers outside the implementation program.
Conclusions—Clinicians identified their own knowledge deficits, workflow integration, and 
longitudinal responsibility as challenges to successful usage of pharmacogenomics in clinical 
practice.
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Introduction
The use of genomic variants to tailor medical therapy is becoming increasingly relevant to 
routine clinical practice, as medications commonly used in primary care and cardiology 
practice acquire new indications for pharmacogenomics testing[1–4]. Advances in 
pharmacogenomics are marked by the expanding number of drug labels featuring 
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pharmacogenomics guidance, pre-prescription testing endorsed by the Food and Drug 
Administration, and the growth of prescribing guidelines by the Clinical Pharmacogenomics 
Implementation Consortium (CPIC)[5–8]. Additionally, laboratory technologies to perform 
multiplexed genotyping are rapidly becoming more affordable and reliable [9]. Together, 
these developments have stimulated the funding of pharmacogenomics implementation 
networks within academic medical centers and integrated health systems [10–13]. Initial 
outreach efforts for pharmacogenomics testing typically focused on specialty care providers. 
As larger numbers of patients undergo testing for a wider number of drug-gene interactions, 
general practitioners are rapidly becoming more involved in applying this new type of data 
in clinical practice.
Translating research knowledge to clinical practice has historically presented multiple 
challenges, requiring changes to process and organizational culture[14]. Advances in the 
science and practice of pharmacogenomics could outpace the preparedness and receptivity 
of physicians and other clinical staff to effectively use the results to tailor therapy. Genomic 
medicine features a complex knowledgebase that is unfamiliar to both patients and 
physicians, many of whom have had no formal training on these concepts [15–18]. Given the 
complexity of the reporting and interpretation, integrating pharmacogenomics results in the 
electronic health record may lead to difficulty with understanding the clinical significance or 
problems in applying results toward individual patient cases [15–17].
The field of pharmacogenomics needs a better understanding of how clinicians are 
responding to genomic data in routine care activities. As part of an evaluation program for a 
large scale pharmacogenomics implementation, PREDICT (Pharmacogenomic Resource for 
Enhanced Decisions in Care and Treatment)[19, 20], we conducted a qualitative study using 
semi-structured interviews with healthcare practitioners. The interviews sought to answer 
two research questions. What are clinician attitudes towards pharmacogenomics in practice? 
What unanticipated barriers are clinicians encountering as they begin using drug-gene 
interactions in routine healthcare practice? Domains addressed by the interviews included 
how participants conceptualized pharmacogenomics, operationalized pharmacogenomic test 
ordering, interpreted results, communicated with patients, and viewed long-term 
responsibility for results. The interviews identified key themes that may highly influence the 
direction of future implementation efforts.
Materials & methods
Study setting & participant recruitment
The study was conducted at Vanderbilt University Medical Center (VUMC), which launched 
PREDICT in 2010[19, 20]. The program pairs a panel-based genotyping with pharmacy 
surveillance and clinical decision support in VUMC’s electronic health record in order to 
facilitate genome-guided prescribing of target medications at the point of care. At initiation, 
PREDICT delivered CYP2C19 genetic results and clinical decision support for selection of 
clopidogrel or alternative antiplatelet therapy; in subsequent years, the implementation 
expanded to include genes and recommendations relevant to warfarin, tacrolimus and 
thiopurine drugs. To date, over 14,500 VUMC patients have been tested within the program, 
the majority of whom receive care in Internal Medicine and Cardiology clinics. We report 
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data from clinicians practicing in these environments within 2010–2013. All of the 
interviews were conducted in 2013 and early 2014.
We developed a purposive sampling plan for interviews along two axes: usage patterns and 
practice domain. The sampling plan solicited users from two types of practice, primary care 
and cardiology, selected because of the indications for the commonly used medications 
targeted by the program. Usage patterns were quantified by the number of orders for the 
PREDICT test. Low usage pattern was defined as < 10 orders summarized over the prior 
year, medium usage was defined as between 10 and 99 orders, and high usage patterns 
defined as > 100 orders for pharmacogenomics testing. We recruited subjects along the two 
sampling axes, contacting potential subjects directly by email or in person and requesting 
their interview participation. Interview subjects were compensated for their time. We 
continued with interviews within each subgroup until we reached a point of data saturation, 
where additional interviews did not yield significant additional knowledge.
Data collection
Semi-structured interviews were selected to assess clinician attitudes and knowledge based 
on prior experience evaluating health information technology and program evaluations[21]. 
Interviews were selected over other approaches such as observation due to the limited 
number of times on any day that a specific clinician might interact with pharmacogenomics 
testing or clinical decision support. Qualitative methods such as interviews are commonly 
used in social science research, and increasingly applied to healthcare research. The methods 
are well-suited to understanding the rationale behind technology usage patterns and 
underlying aspects of clinical decision-making.
Interview questions were developed based on the research questions motivating the study. 
We developed the interview instrument through discussion and iterative refinement by the 
research team, including experts in qualitative research approaches. Research questions were 
divided into categories: role and computer use, meaning and use of pharmacogenomics, 
experiences with PREDICT, pharmacogenomics nomenclature and open-ended feedback. 
Each question category sought to elicit specific feedback regarding pharmacogneomic use in 
practice. Subsequently, we pilot tested the instrument with two interview subjects. Pilot 
testing led to minor changes to the instrument to clarify the phrasing and content of the 
questions. Finally, we arranged interviews in locations convenient to our interview subjects. 
Each semi-structured interview used the same interview script (appendix A), but allowed the 
flexibility to add clarifying questions or to modify questions based on subject responses.
Each interview was conducted by one or two researchers with experience in qualitative 
methods. All interviews were either audio or video recorded, with interview subjects allowed 
to choose between the two options. Interview subjects reviewed a written informed consent 
document prior to the interview beginning, and all interview subjects provided signed 
consent.
Data Analysis
After interviews were completed, the audio or video files were transcribed. Transcribed files 
were then uploaded to Dedoose, a cloud-based data analysis package, specifically developed 
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to support analysis of qualitative and mixed methods data. Users are able to upload files to 
Dedoose in a variety of formats, including text files containing, for example, transcribed 
content of audio- or video-recorded data. Once uploaded to Dedoose, the tool allows users to 
review file contents, tagging text elements and applying codes to them. Dedoose organizes 
the qualitative data throughout analysis and supplies aggregate views of codes and text 
excerpts coded by researchers.
Using Dedoose, we analyzed the data, applying a grounded theory approach to data analysis. 
Grounded theory approaches allow theory to emerge from the data, rather than applying 
existing theoretical frameworks to data analysis [22]. During an initial open coding phase of 
analysis by two separate researchers, data were analyzed to identify and code key concepts 
in the data[23]. A second phase of data analysis involved review of all codes to identify 
common patterns and recurrent themes across interviews. We examined the patterns and 
themes to identify elements and concepts that connected the initially identified themes 
together. Initial patterns and themes that shared common elements (i.e., were similar in 
content and meaning) were aggregated into the themes presented in the results, all grounded 
in the initial interview data [24].
Two researchers working independently reviewed each transcript in Dedoose and applied 
codes to the data to identify elements of interest through an open coding process. Working 
collaboratively, researchers then identified the main themes, looking for recurrent patterns 
and key themes in the assigned codes [25]. The Vanderbilt University Institutional Research 
Board approved the study.
Results
We recruited 15 clinicians from both internal medicine and cardiology and from each of the 
three usage categories. Nine cardiology and six primary care providers were interviewed 
representing four low usage, four medium usage, and seven high usage clinicians. More high 
usage clinicians were interviewed as they expressed a greater diversity of opinions regarding 
the testing and more interviews were required to achieve data saturation. The majority of 
interviewees (13) were attending physicians, as the majority of PREDICT users had this 
role. We also interviewed two nurse practitioners who actively prescribed medications 
targeted by PREDICT and interacted with clinical decision support.
Based on analysis of interview data, we identified three high-level theme categories in the 
data: preparation and knowledge, pharmacogenomics usage in practice, and future 
implementation challenges. Each category consisted of multiple themes incorporating 
related concepts.
Preparation and knowledge
None of the clinicians in our sample had specific coursework or other training in 
pharmacogenomics prior to the program implementation, an expected outcome given the 
early stages of translating pharmacogenomics to practice. Despite the lack of formal 
training, clinicians developed knowledge and understanding of pharmacogenomics concepts 
through various mechanisms. Specialty care providers discussed developing initial 
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pharmacogenomics knowledge prior to the informatics intervention from research studies 
about the relationship between clopidogrel and the gene encoding the metabolizing enzyme, 
CYP2C19, presented in the literature and at academic conferences. Primary care providers in 
our sample had less prior exposure to pharmacogenomic concepts and expressed less 
confidence in their pharmacogenomics knowledge base. One clinician described the 
uncertainties inherent in clinical knowledge by stating, “I feel like the things that I know, I 
know, but I'm fully aware that there's a much larger pool of what can … be applied to that I 
don't know. So, I know my ignorance.”
Interviewers asked each subject, “How do you define the term ‘pharmacogenomics’?”, 
eliciting a wide variety of reactions and responses. Several interview subjects laughed at the 
question, expressing uncertainty about the concept. For example, one respondent stated, “I 
don't know. Trying to identify patient-specific ways that patients use or break down or get 
rid of medications.” Other clinicians responded confidently and concisely. The degree of 
precision and detail in definitions of pharmacogenomics varied widely. For example, some 
subjects responded with a fairly simple definition, “I define it as understanding a patient's 
profile to help you make a better decision about the appropriate medication use.” Other 
subjects provided more detail in their responses, “It’s the use of genetic polymorphisms to 
determine even before first dose… potentially which drug, which dose of the drug, potential 
side effects, adverse effects from the drug. I guess in a nutshell… that would be my 
definition.”
PREDICT implementation initially targeted specialty care providers in cardiology. 
Cardiology clinicians cited outreach efforts by clinical and informatics leaders to promote 
the upcoming pharmacogenomics tool implementation as a key factor in their development 
of knowledge about and use of the testing. Methods used for knowledge dissemination 
included Grand Rounds and smaller practice group meetings. Clinicians typically discussed 
several key clinical and research leaders who provided an initial introduction and ongoing 
dialog related to pharmacogenomics,
“Probably at the department level through larger group presentations. I recall 
[program faculty leader] being an influential voice to introduce this. I also worked 
closely with one of the key members of the pharmacogenomics team…. So, that 
has been a steady source of conversation over the last two years.”
The types of initial exposure to pharmacogenomics discussed by primary care providers 
focused more on general communication channels, such as electronic medical center 
newsletters and journal articles.
Despite outreach efforts, questions remained about rapidly changing pharmacogenomics 
knowledge. One cardiologist described the balance between knowledge dissemination and 
the types of knowledge needed to apply information in practice,
“Well, I think we could be more informed of some of the pharmacogenetic 
principles frankly in a more understandable way than the state-of-the-art grand 
rounds lecture on one hand and the patient communication piece on the other. 
There's something in between that is clear, concise, pitched at the general 
practitioner’s level that is missing in this whole operation.”
Unertl et al. Page 5













Because of the rapid evolution and expansion of pharmacogenomics knowledge, clinicians 
discussed the need for continuing education. Clinicians discussed concerns about their 
knowledge becoming quickly obsolete. One cardiologist summarized this concern by saying,
“I wish I knew more because sometimes I think we, I feel like we practice in a 
vacuum, especially on something so super specialized as this. So, you know it, and 
you learn it, and you know very well in six months what you know is not current. I 
mean, there's no way that it is.”
In summary, we identified both positive aspects and gaps in the outreach efforts related to 
education and concerns by clinicians about continuous engagement to maintain their 
knowledge of research advancements.
Pharmacogenomics usage in practice
Test ordering and reporting—A clear theme across interviews was that clinicians 
understood the rationale for obtaining pharmacogenomics information, but integrating this 
knowledge into healthcare practices raised complex questions and concerns. One strong 
proponent of obtaining pharmacogenomics panel data summarized this view,
“I think more information is always better about patients. So I believe that it's 
important to try to obtain this genetic information, pharmacogenomic information 
on my patients. That's step number one. Step number two is what do you do with 
the information? We're still learning.”
Standard laboratory reporting of genomic test results was sometimes unclear to clinicians, 
leading them to seek answers from the interpretive information present in other sections in 
the EHR. For example,
“There is so much information that comes back when [the laboratory test report] 
shows results that you say, “Okay, I don't know what this means. I'm going to go to 
[the EHR] where it's really simple and it tells me it's a poor metabolizer or 
intermediate metabolizer.” Those are words I can understand as opposed to getting 
all the genetic information.”
Some clinicians felt that even these distilled phenotype terms were difficult to interpret, in 
part because the nomenclature that was familiar to the clinical genetics research community 
was not transparent to end-users.
“I think poor metabolizer is a good word, a good phrase… Indeterminate would 
suggest that we have no idea what the mutation does. Whereas, intermediate… a 
more suitable word might be partial metabolizer.”
Due to the highly specialized content of pharmacogenomics tests, some clinicians expressed 
concern about the clinical relevance and information overload of reporting genomic 
information to the EHR. As one clinician expressed, “One gets diluted, tired, and then 
ignorant of things that are posted on every single patient, especially if we're not using it very 
often.”
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Translating results into clinical decisions—Once tests results were reported, 
clinicians integrated pharmacogenomics test data into their clinical decision-making 
processes to varying degrees. Clinicians expressed strong desires for, as one clinician 
described it, “decision support that's informational that doesn't disrupt the flow of the work.” 
The need for CDS in general to be well integrated into clinical workflow has been a repeated 
theme of informatics research on CDS[26] so the extension of this perspective to 
pharmacogenomics CDS was unsurprising.
Interview subjects provided suggestions for several different approaches to CDS, focused on 
the idea that CDS needs to be clear and concise but also provide the ability to seek out more 
information quickly and easily if desired. One clinician laid out a rationale as follows,
"I'm a very quantitative person… intermediate doesn't mean anything to me. So… 
can you tell me poor metabolizer? Could you quantify that in some way? 10, less 
than 10%? Some number that tells me or even something that's just color coded and 
it says, “Prescribe something else. Don't do these drugs,”
Another physician suggested,
“Most importantly, the information has to be pushed to the ordering physicians so 
that the ordering physician gets the information. With that push has to be very easy 
links to… written advisor statements invented by the experts that tell us what is 
recommended. And then, there should be another link to the original data for 
people that want to know exactly what the evidence is one way or the other.”
Clinicians in our interview sample viewed pharmacogenomics data as just another element 
to integrate into clinical decisions, much like routine laboratory tests. At the same time, they 
pointed out that multiplexed pharmacogenomic testing as assessed by PREDICT 
encompassed potential pharmacogenomics interactions beyond ones that currently have clear 
treatment guidelines in their field. Other subjects expanded on this concept, to discuss how 
the current state of pharmacogenomics knowledge may not give a full picture of the 
potential variation in drug response.
“That's part of the frustration at this particular point with pharmacogenomics, in 
terms of having a patient walk into the door and really not knowing that 
information that you think may be vital to their care in terms of trying to 
individualize their care at that particular point, but as we go forward, as information 
starts to compile and build, connects and make modifications in terms of therapy.”
Clinicians reported that making medical decisions related to pharmacogenomics data 
involved a complex effort to balance cost, risk, and benefit. Alternative medications 
suggested by the literature and adopted by the program for use within CDS could create 
higher out of pocket costs and new safety concerns in addition to the promise of improved 
efficacy. Clinicians discussed the challenges inherent in integrating program guidance with 
the social situation of the patient and uncertainties with how much genome tailored therapy 
would improve outcomes. “I mean it’s a huge financial burden on patients to make the 
change. So we have to prove that it actually changes outcome.”
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Explaining test ordering and results to patients—Initially, clinicians discussed 
pharmacogenomics testing in detail with patients before ordering tests, but reduced the 
amount of explanation over time.
“So, at the beginning, we started all this, I went through this detailed explanation of 
what we were ordering, and what I found from patients is that the response all 
along is, ‘Oh, please order it. It's stupid not to order this particular test. I definitely 
want to know the information.’ At this point, it's become a shorter conversation in 
terms of, ‘I want to do this. I think it's smart. This is why,’ and everybody says, 
‘Fantastic. Please do and can my daughter get it? Can my uncle get it? Can my 
grandmother get it?’”
Other clinicians felt that in-depth explanations of specific pharmacogenomic testing details 
were unnecessary in initial decisions to test.
“I'm usually somebody that likes to simplify things an awful lot for understanding 
for both my patients and for me. So, you know, how can I make this as simple as 
possible so that they get the big picture of why I'm doing the test, but not 
overwhelm them with its purpose.”
Clinicians discussed some of the language they used in explaining pharmacogenomics 
testing to patients,
“I try to explain that this is a piece of the puzzle. That we can get lots and lots of 
people's data and then we can be able to sort of make more, I don't say responsible, 
but medically sound decisions based on evidence and not guess work.”
Clinicians described a clear pattern that, as they became more familiar with this type of 
testing, they began to view the test in a similar light as other clinical tests in terms of 
explanation required before testing. One substantial caveat to this explanation pattern is that 
during the time interviews were conducted, the PREDICT test was institutionally supported 
and offered free of charge to patients. Some clinicians expressed reservations regarding 
whether patients would be receptive to genetic testing once it was charged to their insurance 
plan and they were responsible for co-pays and deductions. For example, one specialty care 
provider stated, “Patients do not want to pay for testing particularly if it's not… if they don't 
see upfront the benefit of it. I think it's going to be harder to convince people that that is 
added value.”
When receiving test results, clinicians faced the challenge of interpreting and 
communicating the information to patients and families. Their level of familiarity with 
pharmacogenomics impacted this interaction.
“I think that you had a lot of clinicians who were blindsided because all of a 
sudden, patients start finding out they were intermediate metabolizers and this is 
before anyone knew what to do with that. And so, I think, you know, you had 
patients asking their doctors, ‘Well, I got this, you know, this is what they said I am. 
You know, what do I do?’ And the doctors would go, ‘Uh, I don't know.’”
In some cases, a sense of lack of preparedness led to conversations with patients being 
conducted in less detail than clinicians would normally pursue. One clinician explained, 
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“The conversations with patients are more on a high level and not so detailed because of that 
sense of unpreparedness.” Clinicians expressed unease about explaining implications of 
results that were of indeterminate or intermediate significance, “You had patients asking 
their doctors for advice based on their pharmacogenomics result before the doctors knew 
how to respond.”
Secondly, specialty care providers felt underprepared to explain drug-gene interactions that 
involved drugs they did not prescribe, “I try very hard to avoid ordering tests that I don’t 
know how to interpret for the patient, or that I can’t… refer them to something regarding 
interpretation.”
Providers expressed interest in a formal set of patient education materials that anticipated 
questions and concerns. “We might benefit from bullet-point thoughts of what patients are 
hearing because we're having to unravel some of their exceeding expectations when they get 
here.”
Future of pharmacogenomics in practice
Ownership and responsibility for results—Providers discussed how the persistent 
nature of pharmacogenomics data presents new challenges related to long-term data 
ownership, responsibility, and liability. For example,
“Does that information [the full range of PREDICT results] remain undiscovered if 
I don't actively push it to the primary care physician or can it automatically get to 
them so that they can use that information for the 48 other drugs that I'm not going 
to be prescribing?”
Clinicians explained a gap between current policies and the range of data in the informatics 
intervention, with several clinicians exploring the need for formal clear policies to explain 
responsibility and ownership for pharmacogenomics data.
“I think it'd be nice if there were some clarity about the responsibility for the 
ordering physician in terms of notifying the other physicians involved in the 
patient's care just so people know exactly what's expected of them when they order 
the test.”
While clinicians felt clear lines of responsibility and ownership were necessary, they 
expressed concerns about the level of pharmacogenomics knowledge among referring 
clinicians outside the academic medical center environment. The need to educate busy 
community clinicians about the results and recommended action was an area that some 
clinicians felt needed to be explored in detail,
“I think it's going to be important to come up with good processes to educate 
referring physicians as well as ordering physicians and specialists on how to handle 
this information. Who do you need to notify? Who's responsible for acting on the 
information? Who's responsible for educating the patients on it as well?”
Although many clinicians came to view pharmacogenomics testing as another routine 
laboratory test in their practices, there were clear concerns about challenges related to the 
persistence of pharmacogenomics data over time.
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Future of pharmacogenomics evidence development
Regardless of how well the pharmacogenomics test ordering and results were integrated into 
clinical practice, subjects discussed the need to continue scientific exploration of outcomes 
related to treatment changes. One clinician discussed the future of pharmacogenomics by 
saying,
“So, [pharmacogenomics testing] has changed my practice even though the 
outcomes data are not there yet. And I feel comfortable about that because my 
change has been validated in a cohort of patients outside of known genetic 
information. In randomized trials. I also think it's important to get into the mindset 
where we are, as, as clinicians, routinely thinking about optimizing drug therapy for 
patients based on their genetics.“
Closing the loop on the current approach to pharmacogenomics was critical to multiple 
clinicians interviewed for this study. As one clinician stated,
“I’m not sure where it’s headed as far as using it for science in terms of having a 
strong database where we’re linking PREDICT data with clinical outcomes.”
Continuing along the path to personalizing treatment decisions for patients based on genetic 
data requires demonstrating the value of this approach, particularly on improving patient 
outcomes.
Discussion
This study provides insights into the barriers facing the dissemination of personalized 
medicine. First, clinicians acknowledged the complexity of genomic data; the unfamiliar 
representations and nomenclature used to describe results led to difficulties with 
interpreting, communicating, and applying the data to clinical care. Strong support was 
expressed for ongoing engagement with the implementation team to keep clinicians updated 
on the latest research results. Providers also strongly supported the use of thoughtfully 
designed and well-integrated CDS tools to facilitate genome-informed decisions. However, 
they identified gaps in the program related to long-term responsibility for genomic risks 
when patients leave the institution, and hand-offs to community providers.
Several prior qualitative and survey studies have identified providers’ concerns about 
incorporating genomic information into their practice. Interviews of hospital pharmacists 
working in Australia indicated their knowledge, education, and time constraints were 
barriers to use of pharmacogenomics.[27] Similarly, surveys of providers about 
pharmacogenomics identified enthusiasm for the concept but infrequent ordering and lack of 
preparation to receive the results [17, 18, 28]. One study with a similar qualitative design 
assessed primary care physician attitudes within the context of the MedSeq randomized 
clinical trial. Interviewed primary care physicians receiving whole genome sequencing 
results and rated the results as less valuable than family history expressing uncertainty about 
how to act on them.[29] Our study, which was conducted within the context of a supportive 
implementation program, reiterated some of the concerns raised by practitioners in the other 
studies regarding new types of data and the impact of personalized medicine on care. 
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However, the target clinician group, clinical context, and content of the genotyping panel 
were unique and these factors likely significantly impact provider attitudes.
Pharmacogenomics testing was viewed by practitioners in our study as similar to other 
laboratory tests, particularly when explaining the need for such testing to patients. 
Practitioners identified, however, that pharmacogenomics results also had different attributes 
from routine laboratory results. Testing was to address specific treatment questions, but the 
PREDICT pharmacogenomics panel test covered a wide range of genetic variants. 
Pharmacogenomics testing creates persistent data whose meaning and interpretation will 
evolve over time. This persistent value requires assignment of long-term responsibility for 
interpretation and management. Ordering clinicians expressed concerns regarding hand-off 
of responsibility for managing drug-gene interactions for drugs not prescribed by the 
ordering clinician. Primary care physicians in the community had limited preparation to 
interpret and manage drug-gene interaction data, raising questions about how long-term 
responsibility for managing drug-gene data can best be transitioned from ordering 
practitioners to referring and general practitioners. Pharmacogenomics testing represents an 
important and emerging frontier in health data, requiring communication, coordination, and 
longitudinal follow up that is rarely handled effectively in the current fragmented structure 
of healthcare.
The study has several limitations. The themes were derived from a small sample of 
clinicians that may not be fully representative of all opinions within our institution or among 
other types of subspecialists who encounter genomic results. We have not compared 
attitudes between primary care physicians and specialists which would require additional 
data from a broader spectrum of clinicians. Indeed, we expect oncologists who have greater 
clinical experience applying molecular diagnostics in practice would be more comfortable 
with genomic results. Although much of the data gathered in this study has broad relevance, 
pharmacogenomics implementations vary widely and some details may be implementation 
specific. Interviews were conducted when the institution supported the cost of 
pharmacogenomics testing; however, clinicians in the study were already anticipating the 
evolution to testing reimbursed by insurance. Costs of testing and treatment alternatives may 
change rapidly with updates to program and insurance policies, and we anticipate further 
evolution of provider perspectives. Finally, all clinicians interviewed were affiliated with an 
academic medical center, leaving a significant area for future research: studying the 
perspectives of healthcare practitioners in the community.
Conclusions and Future Perspective
A qualitative study of clinician views of pharmacogenomics defined gaps in the current 
implementation and suggestions for future improvement. In particular, pharmacogenomics 
implementations need to focus on education of both practitioners and patients. Continuous 
educational outreach may be required to assist with rapid pace of knowledge development. 
Clinical decision support and long-term responsibility for pharmacogenomics panel data are 
important areas to be addressed by new policies and new program features. With the 
emerging implementation of next generation sequencing of both somatic and germline 
variants, we anticipate attitudes will change as additional evidence is generated. Future 
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investigations of clinicians’ views of genomic medicine should include a broad spectrum of 
specialists, including those who have already embraced targeted therapy and those who are 
poised to incorporate targeted therapy into their clinical practice.
Executive Summary
A qualitative study of clinician views of pharmacogenomics highlighted ongoing interest in 
incorporating genomic information into routine clinical care and defined gaps in the current 
pharmacogenomics implementation and suggestions for future improvement. Study subjects 
reported the following themes:
• Preparation and knowledge
– Clinicians expressed support for the idea that pharmacogenomics is 
rapidly becoming part of standard practice
– Clinicians found it challenging to keep pace with the rapid generation 
of new drug-gene interaction evidence without ongoing educational 
support
• Pharmacogenomics usage in practice
– Clinicians expressed concerns about communicating to patients the 
rationale for applying pharmacogenomic results to prescriptions and the 
need to balance genomic information with other clinical, social, and 
financial factors
• Future of pharmacogenomics in practice
– Clinicians expressed unease with taking long-term responsibility for 
genomic variation that was either not directly related to their care plan 
or outside their specialty.
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Appendix: Ethnographic Interview Guide
Role and computer use
Goal: understanding the interview subject’s role in healthcare delivery and interaction with 
health information technology.
1. Can you describe your current role? What types of patients do you primarily see? 
What clinical department(s) do you normally work in?
2. How do you record clinical provider notes? (Examples: StarPanel Notes, 
Dictation, Paper, Quill*)
3. What tools do you use for ordering tests and procedures? (Examples: OPOC, 
VOOM, HEO/WizOrder*))
4. Are there any other health information technology systems that you use?
5. How would you describe your use of computers in healthcare?
Meaning and use of pharmacogenomics
Goal: understanding how interview subjects conceptualize pharmacogenomics and the role 
of pharmacogenomics in healthcare.
1. How do you define the term “pharmacogenomics”?
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2. How were you first introduced to pharmacogenomics?
3. Where have you learned the most about pharmacogenomic testing? (Examples: 
literature, professional meetings, Vanderbilt communications, media)
4. What types of evidence or guidance do you feel is most persuasive in adjusting 
your clinical practice?
5. How has your understanding or interpretation of pharmacogenomics changed 
over time (in general or for a specific drug-gene interaction)?
6. Have you received any informal or formal training in pharmacogenomics? Can 
you tell us more about any training you’ve received?
7. What role does pharmacogenomic testing have in your healthcare practice 
currently? What role do you think it will have in the future? How prepared do 
you feel to order pharmacogenomic tests and apply the results?
Experiences with PREDICT
Goal: gathering self-reported current usage of PREDICT, an example of how the subject 
currently uses PREDICT, and their anticipated future use.
1. How often do you think you order PREDICT tests right now? How often do you 
think you use the results of PREDICT tests?
a. Could you walk us through an example of a time that you used 
PREDICT to order a pharmacogenomic test? Why did you order the 
test?
b. What was the timeline for ordering the test?
c. Did you use the results of the test yourself, or did you pass the results 
onto another provider?
d. How did the patient respond to ordering the test?
2. Could you walk us through an example of a time you used the results from 
PREDICT tests in care?
a. Did the results change your care plan?
b. What would you have done without the results?
c. Was the patient aware that pharmacogenomic data was used in care 
planning?
3. Can you describe some of the reasons why you order PREDICT testing during 
clinical encounters?
4. The PREDICT testing is currently free for patients. What difference, if any, will 
it make to you when PREDICT testing is no longer free?
5. What circumstances would make you hesitate to order a PREDICT test or lead 
you to not act on recommended treatment changes?
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Goal: understanding how phrasing of PREDICT prompts impacts provider understanding of 
those prompts.
1. What are your thoughts on the PREDICT guideline recommendation language 
that is currently displayed? For example, some terms that are used include “poor 
metabolizer” and “intermediate metabolizer.” What do you think of these terms? 
Are there other terms you would suggest for guidelines?
2. Do you think including other types of information such as quantitative estimates 
of risk (e.g., absolute risk, relative risk) would influence your response to 
PREDICT communications?
3. Based on your own experience with pharmacogenomic guideline 
recommendations, could you rank these words from highest to lowest degree of 
obligation? (Note: see list below)
a. Follow up question: could you discuss why you put these terms in this 
particular order?
General
Goal: wrapping up the interview, gathering any other open-ended comments subjects would 
like to share.
1. Do you have any suggestions on how to best integrate pharmacogenomic data 
into clinical workflow?
2. Is there any other feedback you’d like to give about your interaction with 
PREDICT?
3. Are there any questions about pharmacogenomic testing or about PREDICT that 
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* Note: Starpanel notes and Quill are two alternative electronic documentation tools used 
within the institution where all of the study subjects worked. Likewise, OPOC, VOOM, and 
HEO/WizOrder are names of provider electronic order entry tools within the institution.
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